Patni Rajiv
SEC-identified person · CIK 1616200 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Bioxcel Therapeutics, Inc. BTAI ] | Director | filed 2025 - 2026 |
| Quince Therapeutics, Inc. QNCX | Director | filed 2024 - 2025 |
| Reata Pharmaceuticals INC RETA | EVP, Chief R&D Officer | filed 2023 - 2023 |
| Portola Pharmaceuticals INC PTLA | EVP, CMO | filed 2020 - 2020 |
| Adamas Pharmaceuticals Inc ADMS | Chief Medical Officer | filed 2015 - 2019 |
| Tranzyme INC TZYM | Chief Development Officer | filed 2014 - 2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.